Evolv Plant Based Bio-Production
4 known investors
Leverages molecular science to engineer novel ingredients for use in dietary supplements and functional foods.
Also known as Evolv · evolvlife.com
Investors · 4
.jpeg){kind=logo}
Company profile
researched Aug 2026Evolv is a consumer health brand that develops and sells orally administered peptide-based dietary supplements. Its products are positioned as "biomimetics" — engineered molecules intended to mimic the body's own signaling pathways — rather than as pharmaceuticals or conventional supplements. The company states it has three proprietary peptides across its platform and describes its lead ingredient, the EV1 peptide, as a novel molecule produced using Saccharomyces cerevisiae (yeast) as a biological host, engineered to activate the GLP-1 and GIP receptor pathways.
The current catalog consists of Evolv GLP-1, a daily oral tablet marketed for appetite regulation, reduced "food noise," metabolic support and weight loss, and Evolv Grow for her and Evolv Grow for him, oral products marketed for hair growth and reduced shedding based on a GHK-Cu (GHκCU) biomimetic. The company describes its GLP-1 product as the first oral GLP-1 biomimetic and its hair product as the first oral GHK-Cu biomimetic. Marketing claims reference an eight-week randomized, controlled clinical study, citing per-protocol results from the experimental group, and the site features endorsements from family-medicine physicians.
Business model
Direct-to-consumer sales of packaged supplement products through the company's own online store, with both one-time purchases and recurring subscription deliveries at intervals ranging from every two weeks to every twelve weeks; subscriptions carry a discount and free shipping.
Product revenue from consumer purchases. Evolv GLP-1 is listed at $148.00 for a one-time purchase and $125.80 on a 15%-off subscription (stated as $4.19 per day versus $4.93 per day); Grow for her and Grow for him are listed at $108.80.
Traction
Reported outcomes cited on the company site from an eight-week randomized controlled study (per-protocol results, experimental group) include up to 12+ pounds lost, approximately 750 fewer calories consumed per day, up to 4+ inches off the waist, and no reported muscle or hair loss; hair products cite +1.11 cm of hair growth in 14 days.
▸Full profile — market position, technology, go-to-market
Market position
Positions itself as a new category between dietary supplements and prescription drugs — "not a supplement, not a drug, a biomimetic" — competing with prescription GLP-1 medications and traditional weight-management and hair-growth supplements on the basis of oral delivery, absence of prescriptions and stimulants, and claimed lack of harsh side effects.
Claims to be the first oral GLP-1 biomimetic in the world and the first oral GHK-Cu biomimetic for hair, with activation of both GLP-1 and GIP pathways, onset described within about four hours, a daily tablet format, and clinical study support.
Technology
A proprietary oral peptide platform comprising three peptides. The lead EV1 peptide is described as a novel molecule expressed using Saccharomyces cerevisiae (yeast) as a biological host and designed to activate the GLP-1 and GIP receptor pathways for extended periods, formulated with a proprietary delivery formulation into a daily tablet. A separate oral GHK-Cu biomimetic underpins the hair-growth products.
Go-to-market
Online direct-to-consumer storefront with subscription offers, discount codes, verified-buyer testimonials, physician endorsements, and comparison messaging positioning its tablet against prescription GLP-1 drugs and conventional supplements.
Adult consumers seeking weight-management and metabolic support without prescription GLP-1 medications, segmented on the site as "GLP-1 curious" buyers, people plateauing on existing weight-loss efforts, and those seeking long-term maintenance; plus consumers seeking hair-growth and anti-shedding support.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 2
primary sources listed
- Evolv Plant Based Bio-Productionevolvlife.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Evolv Plant Based Bio-Production do?
- Evolv sells oral "biomimetic" peptide supplements for appetite/weight support and hair growth, sold direct to consumers.
- Who are Evolv Plant Based Bio-Production's investors?
- Evolv Plant Based Bio-Production's investors include Anthropy Partners, JAZZ Venture Partners, Juniper, Spacecadet Ventures.